Who was studied?
101 patients: chemotherapy combination 35, TKI combination 36, PRaG 30.
What does the publication report?
The PRaG group had ORR 20.0% and median PFS 4.5 months; no significant OS difference was found between groups.
Safety findings
Adverse reactions were assessed; a complete graded safety comparison is not available in the abstract.
How should we interpret it?
Nonrandomized treatment selection can confound comparisons. The absence of an OS difference must be retained when interpreting the PFS finding.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Efficacy of PRaG therapy in microsatellite-stable metastatic colorectal cancer: a comparative analysis of PD-1/PD-L1 inhibitor-based combination therapies · DOI: 10.1007/s00262-025-04185-y · PMID: 41051603
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.